We have written a number of articles that we hope will be of interest to you. This includes health guides for various medical conditions; news about drug development and regulatory issues related to Health Canada and the FDA; and other health-related topics. Clicking on the title of a Health Guide will take you to information on that medical condition. Or click on one of the listed topics, such as Industry News or Diabetes. You can also access recent articles by scrolling down the page or clicking an article under ‘Recent Articles’.
A groundbreaking study from the University of Auckland has found that a single fecal microbiota transplant (FMT) can provide obese teenagers with years of health benefits. FMT involves transferring gut bacteria from healthy donors to patients—in this case, through capsules swallowed over two days. While the idea may sound unappealing, the results are remarkable. The
Eli Lilly is moving closer to bringing its experimental weight loss pill, orforglipron, to market after releasing positive results from its latest phase 3 clinical trial. The study, called Attain-2, tested the once-daily pill in people who are overweight or obese and also have Type 2 diabetes—a group often harder to treat. The trial found
More Americans are turning to diabetes drugs like Ozempic, not for diabetes, but for weight loss. A new study shows that the use of GLP-1 medications among U.S. adults without diabetes more than tripled between 2018 and 2022. In that time, annual spending on these drugs surged from $1.6 billion to $5.8 billion. GLP-1 drugs,
The FDA has approved Novo Nordisk’s drug Ozempic for a new use: reducing the risk of kidney disease worsening, kidney failure, and death from cardiovascular disease in adults with Type 2 diabetes and chronic kidney disease (CKD). This approval is significant because Ozempic is now the first drug in its class (GLP-1 receptor agonists) with
Novo Nordisk is exploring a higher-dose version of semaglutide to enhance weight loss treatments. In a recent phase 3b clinical trial called STEP UP, a 7.2-mg weekly dose of semaglutide helped participants lose an average of 20.7% of their body weight over 72 weeks. This significantly outperformed the 2.4-mg dose marketed as Wegovy, which led
Researchers have uncovered intriguing potential in kombucha tea, suggesting it might replicate the benefits of fasting without the need for actual fasting. Kombucha, a fermented tea containing a SCOBY (Symbiotic Cultures of Bacteria and Yeasts), was found to alter fat metabolism when its probiotic microbes colonized the gut of test subjects. The study, led by
Two new phase 2 studies suggest that the investigational drug orforglipron, developed by Eli Lilly, shows promise in the treatment of obesity and type 2 diabetes. Currently, GLP-1 agonists (a class of medications utilized in the treatment of type 2 diabetes mellitus and obesity) approved for these conditions are administered via under the skin injection,
A University of Warwick-led study has found that age is no barrier to successful weight loss. There are more than fifty co-morbidities that can be lessened as a person loses weight, including diabetes, psychiatric problems such as depression and anxiety, and mechanical problems like osteoarthritis. According to this study, Obese patients over the age of 60
